Dissident shareholders join Amylin's board
This article was originally published in Scrip
Executive Summary
Amylin Pharmaceuticals has conceded ground in its proxy battle with activist shareholders after relinquishing seats on the company's board. Carl Icahn and Eastbourne Capital have succeeded in placing their handpicked nominees on the biotech's board.